Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best stocks to buy under $20. On September 29, Dyne Therapeutics announced that Japan’s Ministry of Health, Labour and Welfare/MHLW granted Orphan Drug designation for its investigational therapeutic, DYNE-251. This designation is for individuals with Duchenne muscular dystrophy/DMD who have mutations in the DMD gene amenable to exon 51 skipping. The company’s Chief Medical Officer, Doug Kerr, highlighted that data from the ongoing DELIVER trial showed unp ...